Detail akcie Enlivex Ltd. online

Business Summary: Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID-19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand-alone therapy or in combination with other treatments.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Enlivex Ltd revenues was not reported. Net loss decreased 24% to $7.5M. Lower net loss reflects Financial income increase from $528K to $1.6M (income), Research and development expenses - Bala decrease of 13% to $5.9M (expense), Loss on disposal group of assets held fo decrease of 86% to $29K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.50 to -$0.32.